Opdivo® (nivolumab), Yervoy® (ipilimumab) – New indication
October 2, 2020 - The FDA announced the approval of Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
Download PDF
